{"id":35513,"date":"2025-06-18T22:25:44","date_gmt":"2025-06-18T14:25:44","guid":{"rendered":"https:\/\/flcube.com\/?p=35513"},"modified":"2025-06-18T22:26:36","modified_gmt":"2025-06-18T14:26:36","slug":"sanofis-tzield-prescribed-in-boao-lecheng-to-delay-onset-of-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35513","title":{"rendered":"Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes"},"content":{"rendered":"\n

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY<\/a>), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.<\/p>\n\n\n\n

Disease Progression<\/strong><\/p>\n\n\n\n

Type 1 diabetes progresses insidiously and is clinically divided into three stages. In stages 1 and 2, patients typically show no classic symptoms of diabetes, such as polyphagia, polydipsia, polyuria, and weight loss (the “three excesses and one deficiency”). By the time patients are urgently hospitalized due to severe symptoms like persistent nausea, vomiting, or coma\u2014often leading to a “sudden diagnosis”\u2014the disease has usually advanced to stage 3, with near-total loss of pancreatic islet function. Persistent hyperglycemia can trigger diabetic ketoacidosis (DKA), which may cause irreversible long-term damage, including brain injury and kidney failure.<\/p>\n\n\n\n

Patient Population in China<\/strong><\/p>\n\n\n\n

Latest data shows that China has approximately 600,000 Type 1 diabetes patients, ranking third globally. The condition is most prevalent among children and adolescents aged 10\u201314, with incidence rates in this group nearly quadrupling over the past two decades.<\/p>\n\n\n\n

Teplizumab Mechanism<\/strong><\/p>\n\n\n\n

Teplizumab is a monoclonal antibody (mAb) targeting CD3. It protects pancreatic islet \u03b2 cells to delay the onset of type 1 diabetes for nearly 3 years. The therapy was approved in Lecheng in July of last year.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of…<\/p>\n","protected":false},"author":1,"featured_media":35515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[91,39,867],"class_list":["post-35513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boao-lecheng-pilot-zone","tag-diabetes","tag-nasdaq-sny"],"yoast_head":"\nSanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35513\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35513\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-18T14:25:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-18T14:26:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes\",\"datePublished\":\"2025-06-18T14:25:44+00:00\",\"dateModified\":\"2025-06-18T14:26:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1804-1.webp\",\"keywords\":[\"Boao Lecheng pilot zone\",\"Diabetes\",\"NASDAQ: SNY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35513#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35513\",\"name\":\"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1804-1.webp\",\"datePublished\":\"2025-06-18T14:25:44+00:00\",\"dateModified\":\"2025-06-18T14:26:36+00:00\",\"description\":\"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35513\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1804-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1804-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35513#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes - Insight, China's Pharmaceutical Industry","description":"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35513","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes","og_description":"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.","og_url":"https:\/\/flcube.com\/?p=35513","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-18T14:25:44+00:00","article_modified_time":"2025-06-18T14:26:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35513#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35513"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes","datePublished":"2025-06-18T14:25:44+00:00","dateModified":"2025-06-18T14:26:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35513"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35513#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","keywords":["Boao Lecheng pilot zone","Diabetes","NASDAQ: SNY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35513#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35513","url":"https:\/\/flcube.com\/?p=35513","name":"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35513#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35513#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","datePublished":"2025-06-18T14:25:44+00:00","dateModified":"2025-06-18T14:26:36+00:00","description":"Tzield (teplizumab), the world's first and only targeted therapy designed to delay the onset of type 1 diabetes, has been prescribed in the Boao Lecheng medical tourism pilot zone. The product, developed by French major Sanofi (NASDAQ: SNY), is suitable for delaying the progression of type 1 diabetes from stage 2 to stage 3 in adults and children aged 8 years and above.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35513#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35513"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35513#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","width":1080,"height":608,"caption":"Sanofi's Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35513#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1804-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35513"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35513\/revisions"}],"predecessor-version":[{"id":35517,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35513\/revisions\/35517"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35515"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}